Share This Page
Drug Price Trends for EXFORGE HCT
✉ Email this page to a colleague
Average Pharmacy Cost for EXFORGE HCT
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| EXFORGE HCT 10-320-25 MG TAB | 00078-0563-15 | 14.99780 | EACH | 2025-01-14 |
| EXFORGE HCT 10-320-25 MG TAB | 00078-0563-15 | 14.63200 | EACH | 2024-12-18 |
| EXFORGE HCT 10-320-25 MG TAB | 00078-0563-15 | 14.63200 | EACH | 2024-11-20 |
| EXFORGE HCT 10-320-25 MG TAB | 00078-0563-15 | 14.63200 | EACH | 2024-10-23 |
| EXFORGE HCT 10-320-25 MG TAB | 00078-0563-15 | 14.63787 | EACH | 2024-09-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Exforge HCT
Introduction to Exforge HCT
Exforge HCT is a multifaceted antihypertensive medication that combines three active substances: amlodipine, a calcium channel blocker; valsartan, an angiotensin receptor blocker; and hydrochlorothiazide, a diuretic. This combination makes it a unique and effective treatment for essential hypertension in adults whose blood pressure is already adequately controlled with these components[1][4].
Market Overview
Exforge HCT was approved by the FDA and granted marketing authorization by the European Commission in 2009. It is marketed by Novartis Pharmaceuticals and has been a significant player in the antihypertensive market.
Sales Performance
Before the launch of generic versions, Exforge HCT had substantial sales. For instance, in the United States, it had annual sales of approximately $158 million as of September 2014[3].
Generic Competition
The introduction of generic versions by companies like Teva Pharmaceutical Industries Ltd. has significantly impacted the market. Teva was the first to file for a generic equivalent, gaining 180 days of marketing exclusivity. This move has led to a reduction in prices, making the medication more accessible to a wider audience[3].
Pricing and Cost Analysis
Brand Name Pricing
The cost of Exforge HCT tablets can vary depending on the dosage and pharmacy. For example, a supply of 30 tablets of the 10 mg-12.5 mg-160 mg formulation can cost around $387[2].
Generic Pricing
The availability of generic versions has drastically reduced the cost. A supply of 30 tablets of the generic amlodipine/hydrochlorothiazide/valsartan (10 mg-12.5 mg-160 mg) can cost as low as $98.11[2][5].
Price Projections
Impact of Generic Competition
The entry of generic versions is expected to continue driving down prices. As more generic manufacturers enter the market, competition will increase, leading to further price reductions. This trend is likely to make Exforge HCT and its generic equivalents more affordable for patients.
Market Demand
High blood pressure is a prevalent condition, affecting approximately 74 million adults in the US and one in four adults worldwide. The demand for effective antihypertensive medications is high and consistent, ensuring a stable market for Exforge HCT and its generics[4].
Cost Savings
One of the significant advantages of Exforge HCT is the convenience and potential cost savings it offers by combining three medications into one pill. This can reduce insurance co-payments and make treatment more manageable for patients[4].
Clinical Efficacy and Market Impact
Clinical Trials
Clinical trials have demonstrated that Exforge HCT is more effective in reducing blood pressure compared to dual combinations of its components. The maximum dose of Exforge HCT showed significant reductions in both systolic and diastolic blood pressure, making it a preferred option for patients with moderate to severe hypertension[1][4].
Patient Compliance
The combination of three active substances in a single pill enhances patient compliance. Patients are more likely to adhere to their treatment regimen when they have to take fewer pills, which can lead to better blood pressure control and overall health outcomes[1].
Market Trends and Future Outlook
Increasing Demand for Combination Therapies
There is a growing trend towards combination therapies in hypertension treatment. Up to 85% of patients may need multiple medications to control their blood pressure, and Exforge HCT fills this need by providing a single pill solution[4].
Regulatory Environment
The regulatory environment continues to support the approval and marketing of combination therapies. The FDA's approval of Exforge HCT and similar medications indicates a favorable regulatory climate for such treatments[4].
Key Takeaways
- Generic Competition: The introduction of generic versions has significantly reduced the cost of Exforge HCT, making it more accessible.
- Clinical Efficacy: Exforge HCT has proven to be more effective than dual combinations of its components in clinical trials.
- Market Demand: The high prevalence of hypertension ensures a stable and consistent demand for effective antihypertensive medications.
- Cost Savings: Combining three medications into one pill offers convenience and potential cost savings for patients.
- Regulatory Support: The regulatory environment supports the approval and marketing of combination therapies.
FAQs
Q: What are the active ingredients in Exforge HCT? A: Exforge HCT contains amlodipine, valsartan, and hydrochlorothiazide[1].
Q: What is the primary use of Exforge HCT? A: Exforge HCT is used to treat essential hypertension in adults whose blood pressure is already adequately controlled with these components[1].
Q: How does the cost of Exforge HCT compare to its generic version? A: The generic version of Exforge HCT can cost as low as $98.11 for a supply of 30 tablets, significantly lower than the brand name version which can cost around $387 for the same supply[2][5].
Q: What are the benefits of taking Exforge HCT over dual combinations of its components? A: Exforge HCT has shown greater reductions in blood pressure compared to dual combinations and enhances patient compliance by combining three medications into one pill[1][4].
Q: Is Exforge HCT indicated for the prevention of heart attack or stroke? A: No, Exforge HCT is not indicated for the treatment or prevention of heart attack or stroke, but it is used to manage high blood pressure which can reduce the risk of these conditions[4].
Sources
- European Medicines Agency (EMA). Exforge HCT | European Medicines Agency (EMA).
- Drugs.com. Exforge HCT Prices, Coupons, Copay Cards & Patient Assistance.
- Teva Pharmaceutical Industries Ltd. Teva Announces Launch of Generic Exforge HCT® Tablets in the United States.
- Novartis. Video: FDA approves Exforge HCT® - the Only High Blood Pressure Treatment to Combine Three Medications in Single Pill.
- Drugs.com. Amlodipine/hydrochlorothiazide/valsartan Prices, Coupons, Copay Cards & Patient Assistance.
More… ↓
